Systemic Therapy of HR-positive, HER2-negative metastatic Breast Cancer

被引：0
|
作者：
Lorenz, Judith
机构：
来源：
GEBURTSHILFE UND FRAUENHEILKUNDE | 2022年 / 82卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
引用
收藏
页码：257 / 257
页数：1
相关论文
共 50 条
  • [1] Sacituzumab Govitecan in HR-positive HER2-negative metastatic breast cancer
    Nardin, Simone
    Del Mastro, Lucia
    ANNALS OF TRANSLATIONAL MEDICINE, 2023,
  • [2] Ribociclib in HR-positive, HER2-negative breast cancer
    Burki, Talha Khan
    LANCET ONCOLOGY, 2016, 17 (11): : E482 - E482
  • [3] Palbociclib: A Review in HR-Positive, HER2-Negative, Advanced or Metastatic Breast Cancer
    Esther S. Kim
    Lesley J. Scott
    Targeted Oncology, 2017, 12 : 373 - 383
  • [4] Palbociclib: A Review in HR-Positive, HER2-Negative, Advanced or Metastatic Breast Cancer
    Kim, Esther S.
    Scott, Lesley J.
    TARGETED ONCOLOGY, 2017, 12 (03) : 373 - 383
  • [5] Role of everolimus in the treatment of metastatic HER2-negative/HR-positive breast cancer
    Pronzato, Paolo
    FUTURE ONCOLOGY, 2017, 13 (16) : 1371 - 1384
  • [6] Updates to the Management of HR-Positive, HER2-Negative Breast Cancer
    Gradishar, William J.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2024, 22
  • [7] Exemestane plus entinostat in HR-positive/HER2-negative breast cancer?
    Lichert, Frank
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2022, 82 (01) : 18 - 18
  • [8] EU-Approval for Ibrance for Therapy of Patients with HR-positive/HER2-negative Breast Cancer
    Janik, Achim
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 (1-2) : 67 - 67
  • [9] How we treat HR-positive, HER2-negative early breast cancer
    Lopez-Tarruella, Sara
    Echavarria, Isabel
    Jerez, Yolanda
    Herrero, Blanca
    Gamez, Salvador
    Martin, Miguel
    FUTURE ONCOLOGY, 2022, 18 (08) : 1003 - 1022
  • [10] Efficacy, safety, and predictive model of Palbociclib in the treatment of HR-positive and HER2-negative metastatic breast cancer
    Wang, Wei
    Lei, Wenqian
    Fang, Ziru
    Jiang, Ruiyuan
    Wang, Xiaojia
    BMC CANCER, 2024, 24 (01)
12345